上海奕瑞光电子科技股份有限公司独立董事 关于对公司第二届董事会第二十一次会议相关事项的事前认可意见 章成 高永岗 2023 年 8月28日 （以下无正文，为《上海奕瑞光电子科技股份有限公司独立董事关于对公司第二 届董事会第二十一次会议相关事项的事前认可意见》之签署页) 独立董事签字: 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《关于在上市公 司建立独立董事制度的指导意见》、《上海证券交易所科创板股票上市规则》《上 市公司治理准则》以及《上海奕瑞光电子科技股份有限公司章程》等有关规定, 作为上海奕瑞光电子科技股份有限公司（简称"公司")的独立董事,经认真审 阅《关于增加 2023 年度日常性关联交易预计额度的议案》及相关材料，基于独 立判断的立场，发表如下事前认可意见: 我们认为,《关于增加 2023年度日常性关联交易预计额度的议案》所述增加 2023 年度日常性关联交易预计额度符合公司经营业务的发展需要, 价格参照市 场定价协商制定，是一种公允、合理的定价方式,符合交易当时法律、法规的规 定以及交易当时公司的相关制度，且有利于公司的研发、生产经营及长远发展, 未损害公司及其他非关联方的利益，同意 ...

上海奕瑞光电子科技股份有限公司 第二届监事会第二十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 证券代码：688301 | 证券简称：奕瑞科技 公告编号：2023-049 | | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | 一、监事会会议召开情况 2023 年 8 月 28 日，上海奕瑞光电子科技股份有限公司（以下简称"公司"） 以现场及通讯方式召开了第二届监事会第二十次会议（以下简称"本次会议"）， 会议通知已于 2023 年 8 月 24 日以电子邮件形式发出。本次会议由监事会主席丰 华先生主持，会议应出席监事 3 人，实际出席并表决的监事 3 人。本次会议的召 开及表决程序符合《中华人民共和国公司法》、《公司章程》等相关法律法规的规 定。 具体内容详见公司于同日在上海证券交易所网站（http://www.sse.com.cn/） 披露的《奕瑞科技 2023 年半年度报告》及其摘要。 表决结果：同意票 3 票、反对票 0 票、弃权票 0 票。 1 2.审议通过《 ...

我们认为,公司 2023年半年度募集资金的存放和使用符合中国证券监督管理委员 会、上海证券交易所关于上市公司募集资金存放和使用的相关规定,不存在违规使用募 集资金的行为,不存在改变或变相改变募集资金投向和损害股东利益的情况,我们同意 公司《2023年半年度募集资金存放与实际使用情况的专项报告》。 二、关于增加2023年度日常性关联交易预计额度的议案 上海奕瑞光电子科技股份有限公司独立董事 关于对公司第二届董事会第二十一次会议相关议案的独立意见 根据《上海奕瑞光电子科技股份有限公司章程》、《上海奕瑞光电子科技股份有限 公司独立董事制度》等规定,我们作为上海奕瑞光电子科技股份有限公司(以下简称"公 司")的独立董事,基于独立判断的立场,对公司提交第二届董事会第二十一次会议审 议的相关事项发表独立意见如下: 一、关于公司《2023年半年度募集资金存放与实际使用情况的专项报告》的议案 我们认为:公司增加 2023年度日常性关联交易预计额度符合公司经营业务的发展 需要,交易价格公允,符合法律、法规的规定以及相关制度的要求,未损害公司及其他 非关联方的利益，不存在损害中小股东利益的情形，我们一致同意通过该议案。 (本页以 ...

一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 1、2020 年公司首次公开发行股票募集资金情况 经中国证券监督管理委员会出具的《关于同意上海奕瑞光电子科技股份有限 公司首次公开发行股票注册的批复》（证监许可[2020]1823 号）同意，公司首次 公开发行人民币普通股（A 股）1,820 万股，每股发行价格人民币 119.60 元，募 集资金总额为人民币 217,672.00 万元，扣除承销及保荐费用等与发行有关的费用 19,055.06 万元（不含增值税），实际募集资金净额为人民币 198,616.94 万元。以 上募集资金净额已全部到位，经立信会计师事务所（特殊普通合伙）审验并出具 《验资报告》（信会师报字[2020]第 ZA15507 号）予以确认。 1 2、2022 年公司向不特定对象发行可转换公司债券募集资金情况 | 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2023-047 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 上海奕瑞光电子科技股份有限公司 2023 年半年度募集资金存放与实际使用情况的 专项报告 ...

2023 年第一季度报告 单位：元 币种：人民币 证券代码：688301 证券简称：奕瑞科技 转债代码：118025 转债简称：奕瑞转债 上海奕瑞光电子科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期 增减变动幅度 (%) | | 营业收入 ...

| 证券代码：688301 | 证券简称：奕瑞科技 公告编号：2023-039 | | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | 上海奕瑞光电子科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 5 月 10 日（星期三）至 5 月 16 日（星期二）16:00 前 登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 （ir@iraygroup.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海奕瑞光电子科技股份有限公司（以下简称"公司"）分别于 2023 年 3 月 17 日、2023 年 4 月 27 日在上海证券交易所网站（www.sse.com.cn）披露了《2022 年年度报告》《2023 年第一季度报告》，为便于广大投资者更全面深入地了解公 司的经营成果、财务状 ...

Dividend and Share Capital - The company plans to distribute a cash dividend of 29.00 CNY per 10 shares, totaling approximately 210.81 million CNY, which represents 32.87% of the net profit attributable to shareholders [2]. - The company intends to increase its total share capital by 4 shares for every 10 shares held, resulting in an increase of approximately 29.08 million shares, raising the total share capital to approximately 101.77 million shares [2]. - The company has established a cash dividend policy that aligns with its articles of association and shareholder return plan for 2022-2024 [189]. Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion in 2022, representing a year-over-year growth of 25% [12]. - The operating revenue for 2022 was CNY 1,549,116,657.78, reflecting a growth of 30.47% year-on-year, driven by rapid sales growth in dental and industrial products [21]. - The net profit attributable to shareholders was CNY 641,300,445.36, up 32.49% from the previous year, while the net profit after deducting non-recurring gains and losses increased by 51.18% to CNY 516,793,469.55 [21]. - Basic earnings per share rose to CNY 8.84, a 32.53% increase year-on-year, supported by the growth in net profit [21]. - The net cash flow from operating activities was CNY 316,620,618.89, an increase of 27.66% compared to the previous year, attributed to higher sales receipts [21]. Research and Development - The company has invested RMB 200 million in R&D for new technologies, focusing on improving the efficiency of X-ray imaging systems [12]. - The company's R&D investment accounted for 15.41% of operating revenue, an increase of 3.14 percentage points from the previous year [20]. - Research and development expenses increased by 63.87% to RMB 239 million, driven by enhanced R&D team construction and investment [112]. - The company applied for 66 new intellectual property rights during the reporting period, including 37 invention patent applications, and has a total of 398 registered or authorized IP rights [75][76]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2023 [12]. - A strategic acquisition of a local competitor is anticipated to be finalized in Q3 2023, which is expected to increase the company's market share by 10% [12]. - The company aims to develop comprehensive solutions that integrate hardware, software, and applications to improve overall service offerings [37]. - The company plans to deepen cooperation with strategic clients and expand market share in medical and industrial sectors, enhancing global customer relationships [142]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from its accounting firm [2]. - The company has confirmed that all board members attended the board meeting, ensuring accountability for the report's accuracy [2]. - The company has established a comprehensive governance structure to ensure compliance with legal and regulatory standards [147]. - The company’s board of directors included independent members, ensuring compliance with governance standards [175]. Risks and Challenges - The company faces risks related to intellectual property protection and potential technology leaks, which could negatively impact its competitive edge and operational performance [92]. - There is a risk of falling behind in technology and product development if the company fails to respond to revolutionary new technologies in the market [93]. - The company relies on a concentrated supply chain for key raw materials, with over 20% sourced from overseas, which poses risks if suppliers fail to deliver [95]. - The company is at risk of slower market demand and potential inability to digest new production capacity, which could affect overall business performance [109]. Employee and Management - The total number of employees has exceeded 1,200, with over 400 in R&D, representing a year-on-year growth of 57% and 59% respectively, enhancing the company's talent pool [34]. - The company has implemented an employee stock incentive plan, granting shares to 263 employees to enhance motivation and retention [186]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 7.9187 million RMB [171]. - The company is focused on attracting and retaining high-quality talent to support its growth and innovation strategies [144]. Product Development and Innovation - New product development includes the launch of a next-generation Flat Panel Detector, expected to enhance imaging quality by 30% compared to previous models [11]. - The company has developed a high-performance readout chip for digital X-ray detectors, achieving commercial mass production and reaching international product performance levels [66]. - The company has completed the development of core components for CT detectors, including collimators, scintillators, and photodiodes, and is focused on achieving full integration of CT detectors [64]. - The company has developed several types of flat panel detectors and line array detectors to meet diverse market needs in the dental and industrial sectors [58]. Customer Engagement and Satisfaction - Customer satisfaction ratings improved to 90%, reflecting the success of recent service enhancements [159]. - The company is exploring partnerships with local firms to strengthen its supply chain and distribution networks [157]. - The company aims to enhance its customer engagement strategies, aiming for a 40% increase in customer retention rates [163]. Future Outlook - The company provided guidance for 2023, projecting a revenue growth of 25% and aiming to reach 1.875 billion [159]. - Future trends in digital X-ray detectors include advancements towards lower radiation doses, real-time imaging, and 3D rendering capabilities [60]. - The company is actively investing in new product development and technological advancements to maintain competitive advantage [154].